VP-16-213（NSC-141540）与环磷酰胺（NSC-104801）用于晚期乳腺癌患者的II期评估。 - Suppr

Suppr

超能文献

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.

作者信息

Ahmann D L, Bisel H F, Eagan R T, Edmonson J H, Hahn R G, O'Connell M J, Frytak S

出版信息

Cancer Treat Rep. 1976 May;60(5):633-5.

PMID:1036468

Abstract

摘要

相似文献

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer.VP-16-213（NSC-141540）与环磷酰胺（NSC-104801）用于晚期乳腺癌患者的II期评估。

Cancer Treat Rep. 1976 May;60(5):633-5.

Phase II trial of cytembena in patients with advanced ovarian and breast cancer.替莫贝纳用于晚期卵巢癌和乳腺癌患者的II期试验。

Cancer Treat Rep. 1976 Nov;60(11):1655-8.

Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.VP-16-213用于晚期乳腺癌患者的II期评估：西南肿瘤协作组研究

Cancer Treat Rep. 1981 May-Jun;65(5-6):443-5.

Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.

Am J Clin Oncol. 1982 Oct;5(5):515-9.

VP-16 and adriamycin in patients with advanced breast cancer.

Am J Clin Oncol. 1982 Oct;5(5):505-9.

Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma.VP-16-213与双去水半乳糖醇治疗转移性恶性黑色素瘤患者的II期研究。

Cancer Treat Rep. 1976 Nov;60(11):1681-2.

[Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group].

Gan To Kagaku Ryoho. 1986 Sep;13(9):2772-9.

Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.

Chemioterapia. 1986 Apr;5(2):125-7.

[Randomized phase II study with VP-16-213 (etoposide) in the treatment of advanced breast cancer].

Onkologie. 1981 Apr;4(2):80-3. doi: 10.1159/000214883.

Phase II clinical trial of VP-16-213 in ovarian cancer.VP-16-213治疗卵巢癌的II期临床试验。

Cancer Treat Rep. 1981 Mar-Apr;65(3-4):329-30.

引用本文的文献

Chronic oral etoposide in advanced breast cancer.晚期乳腺癌的慢性口服依托泊苷治疗

Cancer Chemother Pharmacol. 1994;33(6):527-9. doi: 10.1007/BF00686513.

Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.

Breast Cancer Res Treat. 1995 May;34(2):185-9. doi: 10.1007/BF00665790.

The podophyllotoxin derivatives VP16-213 and VM26.

Cancer Chemother Pharmacol. 1982;7(2-3):73-80. doi: 10.1007/BF00254525.

[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].依托泊苷（VP 16-213）——一种具有高抗肿瘤活性的鬼臼毒素衍生物（作者译）

Klin Wochenschr. 1981 Nov 2;59(21):1177-88. doi: 10.1007/BF01721212.

Chemotherapy of breast cancer.乳腺癌的化疗

Med Oncol Tumor Pharmacother. 1984;1(3):169-92. doi: 10.1007/BF02934139.

Phase II study with etoposide in previously untreated advanced breast cancer.

Cancer Chemother Pharmacol. 1989;24(4):261-3. doi: 10.1007/BF00257630.

Podophyllotoxin derivative VP 16-213.鬼臼毒素衍生物VP 16 - 213

Cancer Chemother Pharmacol. 1979;3(2):71-80. doi: 10.1007/BF00254976.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验